Zymeworks Inc
NASDAQ:ZYME
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
8.11
17.4
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one ZYME stock under the Base Case scenario is 18.38 USD. Compared to the current market price of 14.29 USD, Zymeworks Inc is Undervalued by 22%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Zymeworks Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for ZYME cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Zymeworks Inc
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Zymeworks Inc
Balance Sheet Decomposition
Zymeworks Inc
Current Assets | 343.8m |
Cash & Short-Term Investments | 297.2m |
Receivables | 23.7m |
Other Current Assets | 22.9m |
Non-Current Assets | 143.4m |
Long-Term Investments | 77.7m |
PP&E | 35.7m |
Intangibles | 18.6m |
Other Non-Current Assets | 11.4m |
Current Liabilities | 83.9m |
Accounts Payable | 3.4m |
Accrued Liabilities | 50.4m |
Other Current Liabilities | 30.1m |
Non-Current Liabilities | 36.3m |
Long-Term Debt | 33k |
Other Non-Current Liabilities | 36.2m |
Earnings Waterfall
Zymeworks Inc
Revenue
|
62.2m
USD
|
Operating Expenses
|
-183.2m
USD
|
Operating Income
|
-121m
USD
|
Other Expenses
|
7.4m
USD
|
Net Income
|
-113.7m
USD
|
Free Cash Flow Analysis
Zymeworks Inc
USD | |
Free Cash Flow | USD |
ZYME Profitability Score
Profitability Due Diligence
Zymeworks Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
Zymeworks Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
ZYME Solvency Score
Solvency Due Diligence
Zymeworks Inc's solvency score is 73/100. The higher the solvency score, the more solvent the company is.
Score
Zymeworks Inc's solvency score is 73/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ZYME Price Targets Summary
Zymeworks Inc
According to Wall Street analysts, the average 1-year price target for ZYME is 17.79 USD with a low forecast of 12.12 USD and a high forecast of 29.4 USD.
Dividends
Current shareholder yield for ZYME is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
ZYME Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Zymeworks Inc. is a biopharmaceutical company. The company is headquartered in Middletown, Delaware and currently employs 286 full-time employees. The company went IPO on 2019-06-24. Its lead product candidate is zanidatamab, a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its product candidate ZW49, combines the design of zanidatamab with its ZymeLink ADC platform, comprised of its cytotoxin and cleavable linker. The firm operates through a number of platforms, including Azymetric, ZymeLink, EFECT and ProTECT. Its Azymetric is a bispecific platform that enables therapeutic antibodies to simultaneously bind multiple distinct locations on a target or to multiple targets. The Company’s ZymeLink is an antibody-drug conjugate (ADC) platform comprised of cytotoxins and the linker technology used to couple these cytotoxins to tumor-targeting antibodies or proteins.
Contact
IPO
Employees
Officers
The intrinsic value of one ZYME stock under the Base Case scenario is 18.38 USD.
Compared to the current market price of 14.29 USD, Zymeworks Inc is Undervalued by 22%.